Catalyst Pharmaceuticals, Inc. - Common Stock (CPRX)
19.68
-0.18 (-0.93%)
NASDAQ · Last Trade: Aug 11th, 12:56 PM EDT
Detailed Quote
Previous Close
19.86
Open
19.73
Bid
19.67
Ask
19.69
Day's Range
19.36 - 19.98
52 Week Range
18.39 - 26.58
Volume
532,717
Market Cap
2.02B
PE Ratio (TTM)
11.92
EPS (TTM)
1.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,427,432
Chart
About Catalyst Pharmaceuticals, Inc. - Common Stock (CPRX)
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for individuals with rare neurological and neuromuscular diseases. The company’s primary emphasis is on conditions like myasthenia gravis, creating targeted treatments that aim to improve patient outcomes and quality of life. Catalyst Pharmaceuticals is committed to advancing its drug pipeline through research, development, and collaboration, striving to address unmet medical needs in the rare disease landscape. With a patient-centered approach, the company aims to transform the treatment paradigm in its specialized therapeutic areas. Read More
CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton myasthenic syndrome (LEMS), amifampridine (FIRDAPSE®), and the tests for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies.
Louis Navellier’s growth investing strategy highlights stocks like Catalyst Pharmaceuticals (CPRX), which shows strong earnings momentum, rising sales, and high profitability. CPRX meets key criteria, including positive earnings revisions, robust revenue growth, and exceptional ROE, making it a compelling growth candidate.
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors.
Catalyst Pharmaceuticals (CPRX) is a value stock with strong fundamentals—low P/E, zero debt, high profitability, and robust growth, making it a standout in biotech.
Catalyst Pharmaceuticals (CPRX) meets Louis Navellier's growth criteria with strong earnings, sales growth, and high profitability, making it an attractive stock for growth investors.
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, profitability, and financial health at an undervalued price, making it a rare biotech stock for value investors.
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks.
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal.
CATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its potential for investors.
Catalyst Pharmaceuticals (CPRX) shows strong fundamentals, high profitability, and zero debt, making it a compelling choice for quality investors. The stock trades at reasonable valuations with solid growth prospects.
